The dual role of empagliflozin: Cardio renal protection in T2DM patients

被引：3
|
作者：
Shafiq, Aimen [1 ]
Mahboob, Eman [1 ]
Samad, Muhammad Ammar [1 ]
Rehman, Mohammad Hassam Ur [1 ]
Tharwani, Zoaib Habib [1 ]
机构：
[1] Dow Univ Hlth Sci, Dow Med Coll, Fac Med, Karachi, Pakistan
来源：
ANNALS OF MEDICINE AND SURGERY | 2022年 / 81卷
关键词：
Empagliflozin; Type 2 diabetes mellitus; Cardio protective; Reno protective; Side effects; COTRANSPORTER; 2; INHIBITOR; TYPE-2; DIABETES-MELLITUS; ESTABLISHED CARDIOVASCULAR-DISEASE; BETA-CELL DYSFUNCTION; DOUBLE-BLIND; SGLT2; INHIBITORS; ADD-ON; KIDNEY-DISEASE; OUTCOMES; RISK;
D O I：
10.1016/j.amsu.2022.104555
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Empagliflozin (Jardiance (R)) is an insulin independent antihyperglycemic agent used in treatment of T2D.The drug is a sodium glucose cotransporter-2 (SGLT2) inhibitor approved in USA and Europe and other countries of the world. As empagliflozin demonstrates cardioprotective and Reno protective properties its prime target are patients having CVD and CKD complicated by T2D. This review sheds light on mechanism of action of the drug and with the help of clinical outcomes establishes the use of empagliflozin in T2D patients.Although empagliflozin is a well-tolerated and easy to administer drug, it has some side effects and contraindications which are discussed in the article to help the reader weigh its beneficial effects against its adverse effect and understand its use in clinical medicine.
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Cardio-renal protection with empagliflozin
    MacIsaac, Richard J.
    Jerums, George
    Ekinci, Elif I.
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (20)
  • [2] Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM
    Nada, Aml Mohamed
    Younan, Mariam Adel
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2021, 12
  • [3] Canagliflozin review - safety and efficacy profile in patients with T2DM
    Jakher, Haroon
    Chang, Tara I.
    Tan, Marilyn
    Mahaffey, Kenneth W.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 209 - 215
  • [4] Therapy of empagliflozin plus metformin on T2DM mice shows no higher amelioration for glucose and lipid metabolism than empagliflozin monotherapy
    Wang, Zhiguo
    Zhou, Ji
    Lu, Mengran
    Liang, Yuwan
    Jiang, Zhengxuan
    Chen, Keyang
    LIFE SCIENCES, 2019, 232
  • [5] Insights into the Role of Renal Biopsy in Patients with T2DM: A Literature Review of Global Renal Biopsy Results
    Tong, Xue
    Yu, Qun
    Ankawi, Ghada
    Pang, Bo
    Yang, Bo
    Yang, Hongtao
    DIABETES THERAPY, 2020, 11 (09) : 1983 - 1999
  • [6] Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Yaribeygi, Habib
    Maleki, Mina
    Sathyapalan, Thozhukat
    Jamialahmadi, Tannaz
    Sahebkar, Amirhossein
    CURRENT MEDICINAL CHEMISTRY, 2023, 30 (25) : 2850 - 2863
  • [7] Predicting renal function decline in patients with T2DM
    Jerums, George
    MacIsaac, Richard J.
    NATURE REVIEWS ENDOCRINOLOGY, 2014, 10 (07) : 381 - 382
  • [8] Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology
    Wang, Anzhu
    Li, Zhendong
    Zhuo, Sun
    Gao, Feng
    Zhang, Hongwei
    Zhang, Zhibo
    Ren, Gaocan
    Ma, Xiaochang
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [9] Empagliflozin's role in early tubular protection for type 2 diabetes patients
    Zhang, Chuangbiao
    Ren, Weiwei
    Lu, Xiaohua
    Feng, Lie
    Li, Jiaying
    Zhu, Beibei
    MOLECULAR MEDICINE, 2024, 30 (01)
  • [10] Survey to Specify SGLT2 Inhibitor Choice in T2DM Management
    Ghosal, Samit
    Joshi, Radhika M.
    Iyer, Rahul N.
    Adsule, Samir M.
    CLINICAL DIABETOLOGY, 2022, 11 (05): : 326 - 332
12345